These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 11259554)

  • 1. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
    Hatzelmann A; Schudt C
    J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
    Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
    J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
    Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
    Manning CD; Burman M; Christensen SB; Cieslinski LB; Essayan DM; Grous M; Torphy TJ; Barnette MS
    Br J Pharmacol; 1999 Dec; 128(7):1393-8. PubMed ID: 10602317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
    Griswold DE; Webb EF; Badger AM; Gorycki PD; Levandoski PA; Barnette MA; Grous M; Christensen S; Torphy TJ
    J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions.
    Barnette MS; Christensen SB; Essayan DM; Grous M; Prabhakar U; Rush JA; Kagey-Sobotka A; Torphy TJ
    J Pharmacol Exp Ther; 1998 Jan; 284(1):420-6. PubMed ID: 9435206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine.
    Boichot E; Wallace JL; Germain N; Corbel M; Lugnier C; Lagente V; Bourguignon JJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):647-53. PubMed ID: 10640302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
    Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
    Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors.
    Essayan DM; Kagey-Sobotka A; Lichtenstein LM; Huang SK
    J Pharmacol Exp Ther; 1997 Jul; 282(1):505-12. PubMed ID: 9223593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
    Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
    Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury.
    Souza DG; Cassali GD; Poole S; Teixeira MM
    Br J Pharmacol; 2001 Nov; 134(5):985-94. PubMed ID: 11682446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
    Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
    Christensen SB; Guider A; Forster CJ; Gleason JG; Bender PE; Karpinski JM; DeWolf WE; Barnette MS; Underwood DC; Griswold DE; Cieslinski LB; Burman M; Bochnowicz S; Osborn RR; Manning CD; Grous M; Hillegas LM; Bartus JO; Ryan MD; Eggleston DS; Haltiwanger RC; Torphy TJ
    J Med Chem; 1998 Mar; 41(6):821-35. PubMed ID: 9526558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE; Houghton C; Sardar N; Withnall MT
    Br J Pharmacol; 1997 Jun; 121(4):743-50. PubMed ID: 9208143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities.
    Trifilieff A; Wyss D; Walker C; Mazzoni L; Hersperger R
    J Pharmacol Exp Ther; 2002 Apr; 301(1):241-8. PubMed ID: 11907180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of PDE4 inhibitors on lipopolysaccharide-induced priming of superoxide anion production from human mononuclear cells.
    Germain N; Corbel M; Belleguic C; Boichot E; Lagente V
    Mediators Inflamm; 2001 Jun; 10(3):117-23. PubMed ID: 11545248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
    Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol.
    Au BT; Teixeira MM; Collins PD; Williams TJ
    Br J Pharmacol; 1998 Mar; 123(6):1260-6. PubMed ID: 9559913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo.
    Cooper N; Teixeira MM; Warneck J; Miotla JM; Wills RE; Macari DM; Gristwood RW; Hellewell PG
    Br J Pharmacol; 1999 Apr; 126(8):1863-71. PubMed ID: 10372831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.